LARYNGOTRACHEAL ANESTHESIA KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LARYNGOTRACHEAL ANESTHESIA KIT (LARYNGOTRACHEAL ANESTHESIA KIT).
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
| Metabolism | Lidocaine primarily metabolized by CYP3A4, to a lesser extent CYP1A2; tetracaine hydrolyzed by plasma esterases; epinephrine metabolized by MAO and COMT. |
| Excretion | Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%). |
| Half-life | Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours. |
| Protein binding | Lidocaine: 60–80% bound primarily to alpha-1-acid glycoprotein (AAG); tetracaine: >90% bound to albumin and lipoproteins. |
| Volume of Distribution | Lidocaine: Vd = 1.1–2.2 L/kg (highly distributed to tissues, especially brain and heart). Tetracaine: Vd = 3–4 L/kg. |
| Bioavailability | Topical: lidocaine 100% (mucosal), tetracaine 100% (mucosal). Oral: not applicable due to high first-pass metabolism. |
| Onset of Action | Topical (larynx/trachea): lidocaine 1–2 min, tetracaine 2–5 min. |
| Duration of Action | Lidocaine: 30–60 min (topical), tetracaine: 60–90 min. Note: Duration shorter in inflamed mucosa; epinephrine may prolong. |
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for lidocaine, which undergoes primarily hepatic metabolism; however, caution in end-stage renal disease (eGFR <15 mL/min) due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated or use only with extreme caution and reduced dose (e.g., maximum 70 mg total). |
| Pediatric use | Weight-based: 1-2 mg/kg (0.25-0.5 mL/kg of 4% solution) of 4% lidocaine via nebulization or atomization, not to exceed 4.5 mg/kg total; maximum 160 mg per dose. |
| Geriatric use | Elderly patients may require dose reduction due to decreased hepatic clearance; initiate at lowest effective dose (e.g., 2-3 mL of 4% lidocaine) and monitor for toxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LARYNGOTRACHEAL ANESTHESIA KIT (LARYNGOTRACHEAL ANESTHESIA KIT).
| Breastfeeding | Lidocaine and tetracaine are excreted into breast milk in very low amounts. Lidocaine milk-to-plasma ratio (M/P) is approximately 0.4. Tetracaine M/P ratio not reported. Topical use results in negligible systemic absorption, making infant exposure minimal. Compatible with breastfeeding; observe infant for signs of local anesthetic toxicity (rare). |
| Teratogenic Risk | Lidocaine and tetracaine are local anesthetics with low systemic absorption when applied topically. Lidocaine crosses the placenta, but at doses used for topical anesthesia, fetal concentrations are minimal. Tetracaine has limited data. In first trimester, theoretical risk of teratogenicity is negligible at clinical doses; however, avoid if possible. Second and third trimesters: No known fetal harm with topical use. High doses or inadvertent intravascular injection could cause maternal toxicity and fetal bradycardia. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ester-type anesthetics (tetracaine) or amide-type (lidocaine); severe hypertension; hyperthyroidism; concurrent use of MAOIs or tricyclic antidepressants (with epinephrine).
| Precautions | Risk of systemic toxicity if applied to broken skin or mucous membranes; caution in patients with cardiac disease, hypertension, or hyperthyroidism; avoid use in patients with severe hypotension or shock; use smallest dose needed. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical application. If large amounts are used on disrupted mucosa or if inadvertent intravascular injection occurs, monitor for maternal CNS and cardiovascular toxicity (seizures, arrhythmias) and fetal bradycardia. Ensure emergency equipment available. |
| Fertility Effects | No known adverse effects on fertility. Lidocaine and tetracaine are not associated with reproductive toxicity. Topical use has no systemic hormonal impact. |